Get the Stockscreener App
38.67
0.03%
-0.010
Protagonist Therapeutics Inc stock is traded at $38.67, with a volume of 347.30K.
It is down -0.03% in the last 24 hours and up +5.45% over the past month.
Protagonist Therapeutics Inc is a clinical-stage biopharmaceutical company having a proprietary technology platform that enables the discovery and development of novel constrained peptide-based drug candidates to address medical needs. Its pipeline products include Rusfertide (PTG-300) and JNJ-2113.
See More
Previous Close:
$38.68
Open:
$38.74
24h Volume:
347.30K
Relative Volume:
0.55
Market Cap:
$2.30B
Revenue:
$45.48M
Net Income/Loss:
$169.95M
P/E Ratio:
14.76
EPS:
2.62
Net Cash Flow:
$230.85M
1W Performance:
-0.54%
1M Performance:
+5.45%
6M Performance:
-3.90%
1Y Performance:
+38.70%
1-Day Range:
$38.36
$39.37
1-Week Range:
$36.34
$39.52
52-Week Range:
$24.22
$48.89
Protagonist Therapeutics Inc Stock (PTGX) Company Profile
Name
Protagonist Therapeutics Inc
Sector
Industry
Phone
(510) 474-0170
Address
7707 GATEWAY BLVD., SUITE 140, NEWARK, CA
Compare PTGX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PTGX
Protagonist Therapeutics Inc
|
38.67 | 2.30B | 45.48M | 169.95M | 230.85M | 2.62 |
|
VRTX
Vertex Pharmaceuticals Inc
|
459.00 | 117.92B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
673.60 | 73.64B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
639.41 | 38.85B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
256.45 | 33.20B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
119.83 | 28.73B | 3.30B | -501.07M | 1.03B | -2.1146 |
Protagonist Therapeutics Inc Stock (PTGX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-06-24 | Initiated | BMO Capital Markets | Outperform |
| Dec-06-24 | Initiated | Goldman | Neutral |
| Nov-05-24 | Initiated | Wedbush | Outperform |
| Sep-24-24 | Initiated | TD Cowen | Buy |
| Sep-09-24 | Initiated | Truist | Buy |
| Oct-30-23 | Initiated | CapitalOne | Overweight |
| May-25-23 | Resumed | Jefferies | Buy |
| Aug-25-22 | Initiated | JMP Securities | Mkt Outperform |
| Feb-11-22 | Initiated | BTIG Research | Buy |
| Oct-12-21 | Upgrade | JP Morgan | Neutral → Overweight |
| Oct-11-21 | Upgrade | Northland Capital | Market Perform → Outperform |
| Sep-20-21 | Downgrade | JP Morgan | Overweight → Neutral |
| May-24-21 | Initiated | JMP Securities | Mkt Outperform |
| May-24-21 | Initiated | Northland Capital | Outperform |
| Jan-06-21 | Initiated | JP Morgan | Overweight |
| Dec-16-20 | Initiated | Piper Sandler | Overweight |
| Sep-18-20 | Reiterated | H.C. Wainwright | Buy |
| Jul-15-20 | Initiated | Jefferies | Buy |
| May-18-20 | Reiterated | H.C. Wainwright | Buy |
| Jul-08-19 | Initiated | H.C. Wainwright | Buy |
| May-09-19 | Upgrade | Stifel | Hold → Buy |
| Dec-06-18 | Initiated | Nomura | Buy |
| Jan-29-18 | Initiated | Stifel | Buy |
| Jul-21-17 | Initiated | BTIG Research | Buy |
View All
Protagonist Therapeutics Inc Stock (PTGX) Latest News
Polycythemia Vera Market Insight, Epidemiology and Market Forecast, 2034: JAKAFI & BESREMi Lead Polycythemia Vera Market, But New Therapies Poised to Disrupt by 2034 - GlobeNewswire Inc.
Protagonist Therapeutics' SWOT analysis: stock poised for growth amid clinical milestones - Investing.com
Jefferies maintains Buy on Protagonist Therapeutics, $57 target - MSN
Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Shares Sold by Yousif Capital Management LLC - Defense World
Will Weakness in Protagonist Therapeutics, Inc.'s (NASDAQ:PTGX) Stock Prove Temporary Given Strong Fundamentals? - Simply Wall St
Analysts Set Protagonist Therapeutics, Inc. (NASDAQ:PTGX) PT at $56.00 - MarketBeat
Stocks Generating Improved Relative Strength: Protagonist Therapeutics - MSN
Protagonist Therapeutics, Inc. (PTGX): A Cheap Biotech Stock to Invest In Now - Insider Monkey
Bleakley Financial Group LLC Has $246,000 Stake in Protagonist Therapeutics, Inc. (NASDAQ:PTGX) - Defense World
Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Receives $56.00 Average PT from Brokerages - Defense World
10 Cheap Biotech Stocks to Invest in Now - Insider Monkey
Protagonist Therapeutics' (PTGX) Market Outperform Rating Reaffirmed at JMP Securities - MarketBeat
Taking the lead: Protagonist Therapeutics Inc (PTGX) - SETE News
HC Wainwright Reaffirms "Buy" Rating for Protagonist Therapeutics (NASDAQ:PTGX) - MarketBeat
Polycythemia Vera Market Predicted to See Upsurge Through 2034, - openPR
Protagonist Therapeutics’ (PTGX) “Buy” Rating Reiterated at HC Wainwright - Defense World
JMP Securities Reiterates “Market Outperform” Rating for Protagonist Therapeutics (NASDAQ:PTGX) - ETF Daily News
Protagonist Therapeutics’ (PTGX) “Market Outperform” Rating Reiterated at JMP Securities - Defense World
Protagonist Therapeutics (NASDAQ:PTGX) Given Market Outperform Rating at JMP Securities - Armenian Reporter
Objective long/short (PTGX) Report - Stock Traders Daily
Truist maintains Buy on Protagonist Therapeutics with $60 target - MSN
Truist maintains Buy on Protagonist Therapeutics with $60 target By Investing.com - Investing.com UK
Caprock Group LLC Acquires New Position in Protagonist Therapeutics, Inc. (NASDAQ:PTGX) - Defense World
JPMorgan Chase & Co. Issues Positive Forecast for Protagonist Therapeutics (NASDAQ:PTGX) Stock Price - MarketBeat
Selling Buzz: Protagonist Therapeutics Inc [PTGX] Chief Medical Officer MOLINA ARTURO MD sells 26,000 shares of the company – Knox Daily - Knox Daily
Financial Metrics Check: Protagonist Therapeutics Inc (PTGX)’s Ratios for Trailing Twelve Months - The Dwinnex
Protagonist Therapeutics Inc (PTGX) deserves closer scrutiny - US Post News
Protagonist Therapeutics (NASDAQ:PTGX) Stock Price Expected to Rise, JPMorgan Chase & Co. Analyst Says - Defense World
Protagonist Therapeutics Announces Closing of Worldwide Rusfertide License and Collaboration Agreement with Takeda - ACCESS Newswire
Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Shares Sold by Moody Aldrich Partners LLC - MarketBeat
Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Position Increased by Nisa Investment Advisors LLC - Defense World
Top Cancer Experts to Review Game-Changing Blood Disorder TreatmentHere's What's Coming - StockTitan
Protagonist Receives $34 Million from Warrant Exercises - ACCESS Newswire
Protagonist Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update - ACCESS Newswire
Protagonist Reports Third Quarter 2023 Financial Results and Provides Corporate Update - ACCESS Newswire
(PTGX) Investment Analysis - Stock Traders Daily
Protagonist Therapeutics (NASDAQ:PTGX) Trading Up 5.6%Time to Buy? - MarketBeat
Polycythemia Vera Pipeline 2024: Clinical Trials Overview, - openPR
Pacer Advisors Inc. Acquires 142,376 Shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX) - MarketBeat
Protagonist Announces Advancement of JNJ-2113 Across Multiple Indications - ACCESS Newswire
Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Shares Sold by Inspire Investing LLC - MarketBeat
Protagonist Therapeutics to Participate in Upcoming Investor Conferences - ACCESS Newswire
Protagonist Therapeutics Announces Oral Presentation on Long-Term Follow-up of Rusfertide Phase 2 REVIVE Study Open Label Extension at the European Hematology Association 2024 Congress - ACCESS Newswire
Protagonist Therapeutics to Participate in the 7th Annual Evercore ISI HealthCONx Conference 2024 - ACCESS Newswire
Market Recap Check: Protagonist Therapeutics Inc (PTGX)’s Positive Finish at 37.80, Up/Down 2.49 - The Dwinnex
Protagonist Announces Positive Topline Results From Phase 3 ICONIC Studies of Icotrokinra (JNJ-2113) in Plaque Psoriasis, a First-in-Class Investigational Targeted Oral Peptide That Selectively Blocks the IL-23 Receptor - ACCESS Newswire
Protagonist Announces Appointment of Newman Yeilding, M.D. as Chief Scientific Advisor - ACCESS Newswire
Protagonist Therapeutics to Participate in the 43rd Annual J.P. Morgan Healthcare Conference 2025 - ACCESS Newswire
52,239 Shares in Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Purchased by Assenagon Asset Management S.A. - MarketBeat
Protagonist Therapeutics Reports Granting of Inducement Awards - ACCESS Newswire
Protagonist Therapeutics CFO Ali Asif reports stock sale - MSN
Protagonist Therapeutics Inc Stock (PTGX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Protagonist Therapeutics Inc Stock (PTGX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| MOLINA ARTURO MD | Chief Medical Officer |
Nov 26 '24 |
Option Exercise |
8.04 |
5,529 |
44,453 |
51,973 |
| MOLINA ARTURO MD | Chief Medical Officer |
Nov 27 '24 |
Sale |
44.70 |
26,000 |
1,162,280 |
46,444 |
| MOLINA ARTURO MD | Chief Medical Officer |
Nov 26 '24 |
Sale |
45.60 |
5,529 |
252,122 |
46,444 |
| Gupta Suneel | Chief Development Officer |
Nov 25 '24 |
Option Exercise |
7.75 |
175,000 |
1,356,000 |
359,611 |
| Gupta Suneel | Chief Development Officer |
Nov 26 '24 |
Option Exercise |
12.17 |
30,450 |
370,576 |
286,174 |
| Gupta Suneel | Chief Development Officer |
Nov 25 '24 |
Sale |
46.04 |
103,437 |
4,762,239 |
256,174 |
| Gupta Suneel | Chief Development Officer |
Nov 26 '24 |
Sale |
45.50 |
19,191 |
873,190 |
266,983 |
| PATEL DINESH V PH D | President and CEO |
Nov 25 '24 |
Option Exercise |
21.58 |
1,727 |
37,269 |
429,935 |
| PATEL DINESH V PH D | President and CEO |
Nov 25 '24 |
Sale |
46.96 |
78,520 |
3,687,299 |
435,208 |
| PATEL DINESH V PH D | President and CEO |
Nov 26 '24 |
Sale |
46.25 |
21,480 |
993,450 |
408,455 |
0.81%
2.06%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):